HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device

HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device

HER2 is a prognostic and predictive biomarker in breast cancer, normally assessed in tumour biopsy and used to guide treatment choices. Circulating tumour cells (CTCs) escape the primary tumour and enter the bloodstream, exhibiting great metastatic potential and representing a real-time snapshot of...

Full description

Bibliographic Details
Main Authors: Cláudia Lopes, Paulina Piairo, Alexandre Chícharo, Sara Abalde-Cela, Liliana R. Pires, Patrícia Corredeira, Patrícia Alves, Laura Muinelo-Romay, Luís Costa, Lorena Diéguez
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
breast cancer
HER2
circulating tumour cells
liquid biopsy
microfluidics
overall survival
Online Access:https://www.mdpi.com/2072-6694/13/17/4446

Internet

https://www.mdpi.com/2072-6694/13/17/4446

Similar Items